American Biosciences (Blauvelt, USA) |
Nanoparticle albumin-bound technology. e.g. paclitaxel-albumin nanoparticles |
Paclitaxel albumin nanoparticles76
|
Baxter Pharmaceuticals (Deerfield, USA) |
Nanoedge technology: particle size reduction was achieved by homogenization, micro-precipitation, lipid emulsion and other dispersed systems. |
Nano-lipid emulsion77
|
BioSante Pharmaceuticals (Lincolnshire, USA) |
Calcium phosphate based nanoparticles were produced for improved oral bioavailability of hormones/proteins and vaccine adjuvants |
Calcium phosphate nanoparticles78
|
ElanPharma International (Dublin, Ireland) |
Nanoparticles (<1 µm) were produced by Wet milling technique using surfactants and stabilizers. The technology was applied successfully in developing apprepitant and reformulation of Sirolimus. |
Nanocrystal drug particle79
|
Eurand Pharmaceuticals (Vandalia, USA) |
Nanocrystal or amorphous drug is produced by breakdown of crystal lattice and stabilized by using biocompatible carriers (swellablemicroparticles or cyclodextrins) |
Cyclodextrin nanoparticle80
|
iMEDDInc (Burlingame, USA) |
Implantable drug delivery system using silicon membrane with nano-pores (10–100 nm) |
Stretchable silicon nanomembrane81
|
pSivida Ltd. (Watertown, USA) |
The solubility and bioavailability of hydrophobic drugs was achieved by incorporating drug particles within the nano-width pores of biocompatible silicon membranes or fibers. |
Silicon nanoparticles |
PharmaSol GmbH (Berlin, Germany) |
High pressure homogenization was used to produce nanostructured lipid particles dispersions with solid contents that provide high-loading capacity for hydrophilic drugs |
Drug encapsulated in lipid nanoparticles69
|
SkyePharmaPlc, (Piccadily, London, UK) |
Nanoparticulate systems of water insoluble drugs were produced by applying high shear or impaction and stabilization was achieved by using phospholipids. |
A polymer stabilizing nano- reactor with the encapsulated drug core69
|